期刊
ANTIVIRAL RESEARCH
卷 145, 期 -, 页码 14-19出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2017.07.006
关键词
Hepatitis B virus; cccDNA; Adeno-associated virus; Immune-competent mouse; Immune-therapeutics
资金
- ANRS of the Universite de Lyon, within the program Investissements d'Avenir [ANR-11-IDEX-0007]
- INSERM of the Universite de Lyon, within the program Investissements d'Avenir [ANR-11-IDEX-0007]
- DEVweCAN LABEX of the Universite de Lyon, within the program Investissements d'Avenir [ANR-11-IDEX-0007, ANR-10-LABX-0061]
- LabEx Ecofect of the Universite de Lyon, within the program Investissements d'Avenir [ANR-11-IDEX-0007, ANR-11-LABX0048]
- EU Infect ERA HBVccc
- LabEx HEPSYS
- Sanofi-INSERM HBV Cure program of Inserm
- CIRI
- CRCL
- Sanofi
Hepatitis B Virus (HBV) persists in infected hepatocytes as an episomal covalently-closed-circular DNA mini-chromosome, called cccDNA. As the main nuclear transcription template, HBV cccDNA is a key replication intermediate in the viral life cycle. Little is known about the mechanisms involved in its formation, maintenance and fate under antiviral therapies. This is mainly due to the lack of small immune-competent animal models able to recapitulate the entire HBV replication cycle, including formation of HBV cccDNA. Here we report that HBV cccDNA can be detected by Southern blot analyses in the liver of C57BL6 mice transduced with AAV-HBV. HBV cccDNA persists in the liver of these animals together with the AAV-HBV episome. We also set up a PCR strategy to distinguish the HBV cccDNA from the AAV-HBV episome. These suggest that the AAV-HBV/mouse model might be relevant to test drugs targeting HBV cccDNA regulation and persistence. (C) 2017 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据